Scandinavian ChemoTech

The order is a continuation of the progress made in the US by ChemoTech's animal care division - Vetiqure, during the last 12 months and the 14 treatments performed by one of their many oncology specialists.  It is the second noteworthy order in the last two months in the USA. The order, initially valued to approximately 1.3 MSEK, includes several installations of vetIQure systems in clinics in the USA over the coming year.

Dr Boostrom, Chief Oncologist at MedVet in North Carolina, says in a comment:

"Following an evaluation of the TSE technology for well over a year, we are committed to bring the TSE technology to our network of specialty animal hospitals and make Vetiqure/VQ Animal Care Inc our preferred supplier of this technology. We have been impressed by the features of the vetIQure device in on-site training and agree with Vetiqure's key opinion leader, Dr. Pamela Schrager, that this has the potential to offer a paradigm shift in the cancer care for companion animals."

"After great clinical success through our Animal Care operation over the last 12 months, and following significant orders in the US and Sweden, we can definitely see the acceptance and value that the TSE innovation can bring to veterinary cancer care.  After receiving the positive clinical reports, and listening to feedback, from treating physicians, we can expect other larger organisations to follow this client and make TSE their preferred choice. It is a very exciting time to be the co-innovator of a therapy that has started to transform from a vision and opportunistic targets into the paradigm change we now are witnessing." - says Mohan Frick, CEO and co-founder of Scandinavian ChemoTech.

About MedVet:

MedVet is a family of emergency and specialty hospitals committed to providing exceptional care for our patients and an unrivaled experience for our clients and referring veterinarians. MedVet is employee owned and veterinarian led which keeps the company grounded in the commitment to providing the best specialty and emergency care available for pets. The MedVet group consists of more than 35 hospitals throughout North America.

For further information please contact:

Mohan Frick, CEO

Phone: +46 (0)10-218 93 00

E-mail: ir@chemotech.se

Certified Adviser: Redeye AB, Phone: +46 (0)8 - 121 576 90

E-mail: certifiedadviser@redeye.se

This disclosure contains information that ChemoTech is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 20-06-2023 15:30 CET.

Scandinavian ChemoTech AB (publ)

ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation™ (TSE), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Redeye AB is the company's Certified Adviser. Read more at: www.chemotech.se.